IRadimed Corporation (NASDAQ: IRMD) — FY 2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. The filing also provides unaudited fourth-quarter results. IRadimed develops and sells MRI-compatible infusion pumps, patient vital-sign monitors, disposables and related services, primarily to hospitals and acute-care facilities.
Financial performance and liquidity
| Metric | FY 2020 | FY 2019 |
|---|---|---|
| Revenue | $31.7 million | $38.5 million |
| Gross profit / margin | $23.6 million / 74.3% | $29.7 million / 77.1% |
| Operating income (loss) | $(0.8) million / (2.4%) | $8.6 million / 22.5% |
| Net income | $1.4 million | $9.6 million |
| Diluted EPS | $0.11 | $0.78 |
| Cash provided by operating activities | $5.8 million | $10.2 million |
| Cash and investments at year-end | $52.0 million | $46.3 million |
| Working capital at year-end | $58.8 million | $53.1 million |
FY 2020 net income included a $2.0 million income-tax benefit; the CARES Act NOL carryback contributed a reported $0.8 million tax benefit. The company reported no borrowings in the balance-sheet figures presented; total liabilities were $9.7 million, including operating lease liabilities. Management said existing cash, investments, operating cash flow and available financing sources should cover projected requirements for at least 12 months from issuance of the financial statements.
Changes versus comparable periods
- Revenue fell 17.7% year over year, primarily because of lower device sales and the impact of COVID-19-related hospital access restrictions and delayed orders.
- Infusion-pump revenue declined 48.1% to $9.4 million; recognized pump units fell to 279 from 519. Vital-sign-monitor revenue was approximately flat at $9.8 million. Disposables, service and other revenue rose 20.3% to $10.7 million.
- U.S. revenue declined 20.7% to $24.5 million; international revenue declined 5.3% to $7.2 million. International sales represented 22.6% of revenue.
- Operating expenses increased 15.6% to $24.3 million despite lower revenue. General and administrative expense included $3.2 million related to the former CEO, including $2.7 million for separation.
- Operating cash flow declined $4.4 million to $5.8 million. Cash and investments increased to $52.0 million, while working capital rose to $58.8 million.
- In Q4 2020, revenue was $8.5 million versus $10.9 million in Q4 2019; net income was $0.6 million versus $3.2 million. Q4 2020 operating income was $0.7 million, compared with $2.2 million a year earlier.
Outlook, risks and notable items
- Management described the future effects of COVID-19 as uncertain, including impacts on MRI procedure volumes, hospital purchasing budgets and access, customer payments, employees, suppliers and distribution. The filing text does not provide a clear numerical 2021 revenue or earnings forecast.
- Key business risks include dependence on a limited number of products, single-source components (including the infusion-pump motor), reliance on one Florida manufacturing facility, lengthy sales cycles and regulatory oversight. The motor supply agreement runs through February 2024.
- EU Medical Device Regulation requirements were expected to increase compliance and recertification demands; the company said its existing CE certificates were valid through May 2024.
- The company disclosed a prior FDA warning letter that had been resolved and a 2016 FDA Form 483 with observations; a related safety alert was closed in August 2019. Future regulatory action or product-quality issues could disrupt sales.
- The Winter Springs headquarters and production facility is leased from an entity controlled by founder, Chairman and CEO Roger Susi. The lease was renewed through May 2024, with further renewal provisions.
- No material pending litigation was identified. The independent auditor issued an unqualified opinion and reported no critical audit matters. Management concluded disclosure controls and internal control over financial reporting were effective as of year-end; the auditor did not express an opinion on internal control.
Important facts for investors to verify
- Whether pump sales recover and the decline in device revenue reverses, particularly given COVID-19-related hospital access and purchasing delays.
- How much of earnings and tax-related cash benefits are repeatable, including the CARES Act carryback and the former CEO separation costs.
- Current operating cash generation, cash and investment balances, and the company’s ability to sustain margins as expenses and product mix change.
- Supply continuity for sole-source components, especially the ultrasonic motor, and compliance progress for applicable FDA and EU requirements.
- Terms, governance and ongoing costs of the related-party facility lease, and any updates to leadership or material contingencies after the filing date.